Related references
Note: Only part of the references are listed.Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
Yihua Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers
Shin Yup Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Pulmonary Pleomorphic Carcinoma A Clinicopathological Study Including EGFR Mutation Analysis
Kyoichi Kaira et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib
Jian Ming Xu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung
Se Hoon Park et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
Giorgio Scagliotti et al.
ONCOLOGIST (2009)
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
K. Tamura et al.
BRITISH JOURNAL OF CANCER (2008)
PIK3CA mutations and copy number gains in human lung cancers
Hiromasa Yamamoto et al.
CANCER RESEARCH (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
G. D'Addario et al.
ANNALS OF ONCOLOGY (2008)
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
Tetsuya Mitsudomi et al.
CANCER SCIENCE (2007)
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
A. G. Pallis et al.
BRITISH JOURNAL OF CANCER (2007)
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
H. Kimura et al.
BRITISH JOURNAL OF CANCER (2007)
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer
Shuji Ichihara et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung
Shin Myung Kang et al.
CANCER (2007)
Phase II clinical trial of chemotherapy-naive patients >= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
PIK3CA mutation status in Japanese lung cancer patients
Osamu Kawano et al.
LUNG CANCER (2006)
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
H. Asahina et al.
BRITISH JOURNAL OF CANCER (2006)
Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung
S Toyooka et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer
XT Zhang et al.
ANNALS OF ONCOLOGY (2005)
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer
XL Mu et al.
CLINICAL CANCER RESEARCH (2005)
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
TY Chou et al.
CLINICAL CANCER RESEARCH (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
SW Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
W Pao et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Predictors of the response to gefitinib in refractory non-small cell lung cancer
KS Kim et al.
CLINICAL CANCER RESEARCH (2005)
EGFR mutations in non-small-cell lung cancer:: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
A Marchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
